跳至主要内容
临床试验/NCT00100958
NCT00100958已完成1 期

Phase I Ascending Single Dose Pharmacokinetics (PK) and Safety Study of 3,3' Di-Indolymethane (DIM) Nutritional Product

University of Kansas2 个研究点 分布在 1 个国家开始时间: 2004年11月最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
试验地点
2

研究概览

简要总结

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of indole-3-carbinol may prevent cancer.

PURPOSE: This randomized phase I trial is studying the side effects and best dose of indole-3-carbinol and to see how well it works compared to placebo in preventing cancer in healthy participants.

详细描述

OBJECTIVES:

Primary

  • Determine the maximum tolerated dose of indole-3-carbinol in healthy participants.
  • Determine the safety and tolerability of this drug in these participants.
  • Determine the pharmacokinetics of this drug in these participants.

Secondary

  • Determine the effects of this drug on selected markers of sexual function in these participants.
  • Determine the effects of this drug on markers of susceptibility to cancer in these participants.

研究设计

研究类型
Interventional
分配方式
Randomized
主要目的
Prevention
盲法
Double

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验

Indole-3-Carbinol in Preventing Cancer in Healthy... | 临床试验